Alnylam to Webcast TTR Investor Webinar

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, has announced an upcoming TTR Investor Webinar scheduled for March 24, 2026, at 9:30 am ET. The event will be accessible via the Investors section of Alnylam's website and will include a replay available 48 hours post-event.

An important highlight of the webinar is the one-year anniversary of the U.S. FDA's approval of AMVUTTRA® for treating transthyretin amyloid cardiomyopathy (ATTR-CM). The session aims to outline Alnylam's advancements in supporting patients with ATTR-CM and its long-term growth within its TTR franchise. Senior leaders from the company, including Tolga Tanguler (Chief Commercial Officer), John Kennedy (SVP, TTR Franchise Global Commercialization Lead), Mark Soued (SVP, Head of U.S. & TTR Lead), and Sameer Bansilal (VP, Medical Affairs, TTR Disease Area Lead), will share insights during the webinar.

Alnylam has been at the forefront of RNAi therapeutics for over twenty years, transforming groundbreaking scientific discoveries into approved medicines, with six currently available. The company’s portfolio has reached over 70 countries and is complemented by a strong pipeline of innovative therapies. Recognized for its exceptional workplace culture and commitment to social responsibility, Alnylam is advancing its "Alnylam 2030" strategy designed to enhance patient care and propel innovation.

Investors and stakeholders interested in the developments of Alnylam Pharmaceuticals and its TTR franchise are encouraged to participate in the upcoming webinar for a comprehensive overview of the company's trajectory in the RNAi field. Further information can be found on Alnylam's official website and social media platforms.

As Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) gears up to conduct its TTR Investor Webinar on March 24, 2026, investors should consider a few key factors that could influence their investment strategy regarding the company.

Firstly, the webinar marks a critical moment, celebrating one year since the U.S. FDA approval of AMVUTTRA® for transthyretin amyloid cardiomyopathy (ATTR-CM). This serves as a pivotal milestone for Alnylam as it not only underscores the success of their flagship TTR franchise but also highlights the effectiveness of their RNA interference (RNAi) platform. Investors should watch for insights on the drug’s performance in the market and any updates relating to sales figures and patient access, which will be critical for assessing the long-term viability of this product.

Furthermore, Alnylam’s continued investment in its robust pipeline, alongside the expansion of its international presence in over 70 countries, suggests a strong potential for future growth. The company’s strategic focus outlined through its "Alnylam 2030" initiative aims at bolstering innovation, which may translate into additional product approvals and market opportunities.

Moreover, with the involvement of senior executives at the webinar, investors should pay close attention to any guidance provided regarding future clinical programs or commercial strategies for the TTR franchise. This could offer insight into the company’s prioritization, resource allocation, and potential revenue growth areas.

In summary, while Alnylam’s historical performance is commendable, investors should remain cautious and consider the content of the upcoming webinar as it could provide critical guidance for the stock's future trajectory. Monitoring the responses to questions during the webinar may also yield valuable insights into the management’s confidence and how they plan to navigate future challenges in the biopharmaceutical landscape.